Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang, Chia‐Jui Yen, Julien Edeline, Su Pin Choo, Chia‐Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean–Frédéric Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Éric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier, Carmen Guillén‐Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea P. Myers, Jean‐Pierre Delord (2022). A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. , 41(1), DOI: https://doi.org/10.1186/s13046-022-02383-5.
Article67 days agoClinical case- reconstruction in region of inflammatory cystic injury with the use of recombinant growth hormone (RhGh) with liofilized bovine bone (Bio-Oss)
L. Tessinari, Rogério Miranda Pagnoncelli, Massimo Filippi, Martin Schüler (2019). Clinical case- reconstruction in region of inflammatory cystic injury with the use of recombinant growth hormone (RhGh) with liofilized bovine bone (Bio-Oss). , 48, DOI: https://doi.org/10.1016/j.ijom.2019.03.835.
Article68 days agoErdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Josep Tabernero, David A. Reardon, Christophe Massard, Anna Minchom, Iwona Ługowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Ademi Santiago-Walker, Spyros Triantos, Hussein Sweiti, Yohann Loriot, Omar Carranza, Martin Alberto Greco, Jermaine Coward, Anthony M. Joshua, Christos S. Karapetis, Christopher D. Hart, Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang (2023). Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. , 24(8), DOI: https://doi.org/10.1016/s1470-2045(23)00275-9.
Article67 days agoErdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Josep Tabernero, David A. Reardon, Christophe Massard, Anna Minchom, Iwona Ługowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Ademi Santiago-Walker, Spyros Triantos, Hussein Sweiti, Yohann Loriot, Omar Carranza, Martin Alberto Greco, Jermaine Coward, Anthony M. Joshua, Christos S. Karapetis, Christopher D. Hart, Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang (2023). Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. , 24(8), DOI: https://doi.org/10.1016/s1470-2045(23)00275-9.
Article67 days agoErdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Josep Tabernero, David A. Reardon, Christophe Massard, Anna Minchom, Iwona Ługowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Ademi Santiago-Walker, Spyros Triantos, Hussein Sweiti, Yohann Loriot, Omar Carranza, Martin Alberto Greco, Jermaine Coward, Anthony M. Joshua, Christos S. Karapetis, Christopher D. Hart, Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang (2023). Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. , 24(8), DOI: https://doi.org/10.1016/s1470-2045(23)00275-9.
Article67 days ago